通过DNA免疫保护小鼠免受致死性柯萨奇病毒B3感染。
Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization.
作者信息
Henke A, Wagner E, Whitton J L, Zell R, Stelzner A
机构信息
Institute of Virology, Medical Center, Friedrich Schiller University, 07745 Jena, Germany.
出版信息
J Virol. 1998 Oct;72(10):8327-31. doi: 10.1128/JVI.72.10.8327-8331.1998.
Abstract
Vaccination with DNA and recombinant vaccinia viruses (rec.VV) has been studied with the coxsackievirus B3 (CVB3) model system. Plasmids encoding all structural proteins of CVB3, when injected intramuscularly, induced only low levels of virus-specific antibodies. However, DNA vaccination with the major structural protein VP1 protected 72.2% of mice from lethal challenge, whereas VP1 expressed by rec.VV was much less efficient.
摘要
已利用柯萨奇病毒B3（CVB3）模型系统对DNA疫苗和重组痘苗病毒（rec.VV）疫苗接种进行了研究。编码CVB3所有结构蛋白的质粒经肌肉注射后，仅诱导产生低水平的病毒特异性抗体。然而，用主要结构蛋白VP1进行DNA疫苗接种可使72.2%的小鼠免受致死性攻击，而rec.VV表达的VP1效率则低得多。
相似文献
1
Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization.
J Virol. 1998 Oct;72(10):8327-31. doi: 10.1128/JVI.72.10.8327-8331.1998.
2
VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment.
Front Immunol. 2019 Nov 8;10:2564. doi: 10.3389/fimmu.2019.02564. eCollection 2019.
3
Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Vaccine. 2005 Feb 25;23(14):1672-9. doi: 10.1016/j.vaccine.2004.10.008.
4
Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
Vaccine. 2004 Sep 9;22(27-28):3603-12. doi: 10.1016/j.vaccine.2004.03.033.
5
AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Front Cell Infect Microbiol. 2017 Jun 8;7:247. doi: 10.3389/fcimb.2017.00247. eCollection 2017.
6
Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Vaccine. 2011 Sep 16;29(40):6894-902. doi: 10.1016/j.vaccine.2011.07.049. Epub 2011 Jul 29.
7
Co-expression of interleukin-2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice.
Antiviral Res. 2004 Nov;64(2):131-6. doi: 10.1016/j.antiviral.2004.06.009.
8
Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.
Clin Vaccine Immunol. 2013 Nov;20(11):1743-51. doi: 10.1128/CVI.00466-13. Epub 2013 Sep 11.
9
Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Antiviral Res. 2017 Apr;140:121-132. doi: 10.1016/j.antiviral.2017.01.020. Epub 2017 Jan 28.
10
Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Vaccine. 2012 Mar 16;30(13):2301-8. doi: 10.1016/j.vaccine.2012.01.061. Epub 2012 Jan 31.
引用本文的文献
1
Vaccines against Group B Coxsackieviruses and Their Importance.
Vaccines (Basel). 2023 Jan 27;11(2):274. doi: 10.3390/vaccines11020274.
2
Intein-mediated backbone cyclization of VP1 protein enhanced protection of CVB3-induced viral myocarditis.
Sci Rep. 2017 Feb 2;7:41485. doi: 10.1038/srep41485.
3
A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis.
Vaccine. 2014 Jun 30;32(31):3917-26. doi: 10.1016/j.vaccine.2014.05.052. Epub 2014 May 27.
4
Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.
Hum Vaccin Immunother. 2014;10(5):1284-94. doi: 10.4161/hv.28333. Epub 2014 Mar 10.
5
Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis.
BMC Cardiovasc Disord. 2013 Nov 14;13:100. doi: 10.1186/1471-2261-13-100.
6
Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.
Mol Biotechnol. 2013 Oct;55(2):179-202. doi: 10.1007/s12033-013-9674-4.
7
Ribosomal Initiation Complex Assembly within the Wild-Strain of Coxsackievirus B3 and Live-Attenuated Sabin3-like IRESes during the Initiation of Translation.
Int J Mol Sci. 2013 Feb 25;14(3):4400-18. doi: 10.3390/ijms14034400.
8
Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo.
Arch Virol. 2009;154(4):601-7. doi: 10.1007/s00705-009-0346-4. Epub 2009 Mar 17.
9
Molecular analysis of the role of IRES stem-loop V in replicative capacities and translation efficiencies of Coxsackievirus B3 mutants.
Mol Biol Rep. 2009 Feb;36(2):255-62. doi: 10.1007/s11033-007-9174-3. Epub 2007 Nov 20.
10
Deletions within the 5'UTR of coxsackievirus B3: consequences for virus translation and replication.
Virology. 2007 Mar 30;360(1):120-8. doi: 10.1016/j.virol.2006.09.041. Epub 2006 Nov 3.
本文引用的文献
1
DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site.
Vaccine. 1997 Apr;15(5):553-60. doi: 10.1016/s0264-410x(97)00213-2.
2
A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.
J Virol. 1996 Nov;70(11):7811-8. doi: 10.1128/JVI.70.11.7811-7818.1996.
3
High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
Scand J Infect Dis Suppl. 1993;88:103-8.
4
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11478-82. doi: 10.1073/pnas.90.24.11478.
5
DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection.
J Virol. 1995 Apr;69(4):2684-8. doi: 10.1128/JVI.69.4.2684-2688.1995.
6
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice.
J Virol. 1995 Oct;69(10):5929-34. doi: 10.1128/JVI.69.10.5929-5934.1995.
7
Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides.
Virology. 1994 May 1;200(2):381-9. doi: 10.1006/viro.1994.1202.
8
The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.
J Virol. 1995 Nov;69(11):6720-8. doi: 10.1128/JVI.69.11.6720-6728.1995.
9
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.
J Virol. 1984 Mar;49(3):857-64. doi: 10.1128/JVI.49.3.857-864.1984.
10
Induction of neutralizing antibodies by the coxsackievirus B3 virion polypeptide, VP2.
Virology. 1980 Jul 30;104(2):426-38. doi: 10.1016/0042-6822(80)90345-1.
Zotero 插件